First Clinical Target of ERA | Human Skin | Part V | Dr. Vittorio Sebastiano | Stanford University

#Sebastiano #ERA #Stanford #turnbio #healthspan #aging #reprogramming #Epigenetic
Dr. Vittorio Sebastiano is an Assistant Professor at Stanford University. He has over 15 years of research experience in Developmental Biology, Nuclear Reprogramming, Stem Cell Biology and Regenerative Medicine. His lab has established a new technology named ERA (Epigenetic Reprogramming of Aging). ERA is based on the ideas of cellular reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology has been patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder and Chair of the Scientific Advisory Board. The company is now developing partial cellular reprogramming techniques to reverse cellular aging. A major cause of aging is thought to be the errors that accumulate in the epigenome, the system of proteins that packages the DNA and controls access to its genes. Dr. Vittorio Sebastiano and his colleagues are working on a way to reverse these errors and walk back the cells to their youthful state. And to show that this process does indeed restore the cells’ vigor and eliminate signs of aging.
In this Video, Dr. Sebastiano will discuss the initial targets for his technology and share his valuable opinion on extending healthspan.
Links:-
Transient non-integrative expression of nuclear reprogramming factors promotes multifaceted amelioration of aging in human cells pubmed.ncbi.nlm.nih.gov/32210226/
Turn Biotechnologies www.turn.bio/science